Microsoft Strikes Partnership with Paige To Advance Cancer Diagnostics and Treatment

Microsoft has announced a collaboration with Paige, a global provider of end-to-end digital pathology solutions and clinical AI applications. The partnership will apply the power of artificial intelligence (AI) to digital pathology images to develop and deliver a new generation of clinical applications and computational biomarkers to transform cancer diagnosis and patient care. Microsoft will also make a strategic investment in Paige to accelerate the development and deployment of life-saving AI diagnostics.

Through the collaboration, Microsoft will scale Paige’s technology globally and accelerate the adoption of AI in digital pathology.

Paige will use Microsoft Azure as its cloud provider for the Paige Platform, a comprehensive solution to power a lab’s digital pathology workflow that consists of data management, cloud storage options and FullFocus, an FDA-cleared whole-slide image viewer. 

As part of this collaboration, Paige will become a Microsoft Cloud for Healthcare partner and enable Microsoft to enhance its own offerings for healthcare customers.

Clinical AI applications have the potential to help pathologists diagnose cancer more confidently and efficiently, with the ultimate goal of improving patient care. Paige is currently the only company to have received FDA approval for an AI algorithm in pathology. Paige puts the power of AI into the hands of pathologists by developing novel AI applications on a powerful platform, making it easy to deploy AI in laboratories globally.

Paige will work with other entities, including Microsoft Research on developing large scale machine learning models to push the boundaries of research in oncology and pathology. Paige is also working with Nuance, a Microsoft company, on integrating their offering with Nuance’s Precision Imaging Network.

Join the HealthXL Meeting on ‘Increase DTx Market Access and Adoption via Precision Patient Engagement’ on 18th January. Click here to Request to Join. 

Click here to read the original news story.